Skip to main
HOLX
HOLX logo

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 23%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hologic is positioned for positive financial performance due to strong anticipated organic revenue growth of 5-7%, driven by robust procedure volume increases, impactful new product launches, and strategic tuck-in acquisitions across its Diagnostics, Breast Health, and GYN Surgical segments. The company's bull case scenario envisions revenue growth accelerating into the high single digits (7-9%) and margin expansion of over 50 basis points, contributing to projected earnings growth between 8-12%. Furthermore, Hologic's solid balance sheet and limited leverage support its potential for improved operating efficiencies and business performance, enhancing the overall investment outlook.

Bears say

Hologic faces a negative outlook primarily due to expected revenue growth slowing to low-single digits (1-4%), driven by weakness in its key segments of Diagnostics and Breast Health, which are crucial for overall performance. The company has seen disappointing returns over the past three to five years and struggles with re-accelerating growth post-COVID amid a challenging economic environment that could further reduce demand for its products and services. Additionally, risks such as a slowdown in hospital capital spending, potential market share loss, and integration challenges from recent acquisitions compound the uncertainty around Hologic's future profitability and operational margins.

Hologic (HOLX) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 23% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Hold based on their latest research and market trends.

According to 13 analysts, Hologic (HOLX) has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.